SLN news

Silence Therapeutics plc has executed a definitive transaction agreement to be acquired by Merck KGaA, Darmstadt, Germany, in a scheme of arrangement accepted by shareholders.

Silence Therapeutics announced that divesiran met its primary efficacy endpoint in a Phase 2 trial for polycythemia vera, with high response rates and no new safety findings. This achievement supports its potential best-in-class profile and anticipates the initiation of a Phase 3 trial later this ye…

The company reported cash and equivalents of $72.1 million and a decrease in R&D expenses for Q2 2026, driven by completion of zerlasiran Phase 3 readiness and reduced personnel costs.

Silence Therapeutics filed an exhibit documenting the 2026 corporate presentation and associated forward-looking statements. This filing provides market participants with the material necessary to assess strategic objectives and future projections.

Silence Therapeutics presented Phase 1 follow-up data showing divesiran reduced phlebotomy requirements from 80 procedures to 5 during treatment, with benefits persisting post-dose. Phase 2 results are expected in August 2026, potentially supporting a best-in-class profile for this first-in-class si…